Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) — Cash Flow Quality Index
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Cash Flow Quality Index of 0.51x as of September 2025. Operating cash flow of CN¥68.66 Million is below net income of CN¥134.49 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Sinopep-Allsino Biopharmaceutical Co. Lt assets under control for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Sinopep-Allsino Biopharmaceutical Co. Ltd. A across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Sinopep-Allsino Biopharmaceutical Co. Lt tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2017–2025)
Year-by-year earnings quality comparison for Sinopep-Allsino Biopharmaceutical Co. Ltd. A. For live market cap and the full company financial profile, see Sinopep-Allsino Biopharmaceutical Co. Lt (688076) total market value.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.05x | CN¥681.24 Million | CN¥332.42 Million | ▲ +104.8% |
| 2024 | 1.00x | CN¥400.12 Million | CN¥399.82 Million | ▼ -53.4% |
| 2023 | 2.15x | CN¥350.21 Million | CN¥162.94 Million | ▲ +800.9% |
| 2022 | 0.24x | CN¥29.29 Million | CN¥122.77 Million | ▼ -85.6% |
| 2021 | 1.66x | CN¥180.75 Million | CN¥108.81 Million | ▲ +41.0% |
| 2020 | 1.18x | CN¥141.38 Million | CN¥120.03 Million | ▲ +14.4% |
| 2019 | 1.03x | CN¥46.14 Million | CN¥44.81 Million | ▼ -52.1% |
| 2018 | 2.15x | CN¥96.06 Million | CN¥44.68 Million | ▲ +711.3% |
| 2017 | 0.26x | CN¥11.11 Million | CN¥41.93 Million | — |